1. Any drug that works has a target

   • James O. Armitage

   Editorial 23 September 2006 Pages: 179 - 180

2. ErbB4 expression in squamous cell carcinoma of the head and neck

   • Rami Ben-Yosef
   • Sylvia Marmor
   • Akiva Vexler

   Original Research 08 September 2006 Pages: 181 - 185

   

3. The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents

   • Elias Jabbour
   • Jorge Cortes
   • Hagop Kantarjian

   Review 30 September 2006 Pages: 186 - 196

   

4. Apoptosis: mechanisms and implications for cancer therapeutics

   • Monica M. Mita
   • Alain C. Mita
   • Anthony W. Tolcher

   Review 06 October 2006 Pages: 197 - 214

   

5. Angiogenesis and antiangiogenic treatment in lung cancer

   • J. F. Morère
   • J. M. Brechot
   • R. Etessami

   Review 23 September 2006 Pages: 215 - 219

6. Phase I and II clinical trial design for targeted agents

   • Richard L. Schilsky

   Perspectives 03 October 2006 Pages: 220 - 227

   

7. Breast cancer clinical practice recommendations from Saint-Paul-de-Vence: excerpts concerning targeted therapies

   • M. Namer
   • J. Gligorov
   • on behalf of the working group of Saint-Paul-de-Vence Recommendations (SPVR)

   Day-to-day Practice 12 October 2006 Pages: 228 - 238

   

8. VEGF as a target

   • Stanislas Ropert
   • Jean Plouët

   Cancer Concepts 11 October 2006 Pages: 239 - 240